Compare Johnson & Johnson (JNJ) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Strategy Inc. — how do they compare? Johnson & Johnson trades at $256.22 (market cap $618.09B), while Strategy Inc. trades at $154.9 (market cap $60.40B). The key difference: Johnson & Johnson is far larger — about 10.2× Strategy Inc.'s market cap, and Johnson & Johnson pays a 2.09% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Strategy Inc. for 112 Days on average.
| JNJ | MSTR | |
|---|---|---|
Market Cap | $618.09B | $60.40B |
Volume | 6,050,983 | 23,421,830 |
Sector | Health | Technology |
52-Week High | $278.43 | $320.29 |
52-Week Low | $186.00 | $82.31 |
Typical Hold Time | 129 Days | 112 Days |
Enterprise Value | $646.37B | $79.16B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
MSTR stock trades at $153.37, down 6.79% today, reflecting volatility despite a bullish technical signal. The company reported a net loss of $3.85B in 2025 with a negative net income margin of -6,102.96%, though revenue grew slightly to $477.23M. Analyst consensus remains optimistic with a $252 price target, but earnings misses in recent quarters highlight operational challenges.
The outlook hinges on improving profitability and Bitcoin market stability, offering upside if earnings rebound. Key risks include persistent losses, high debt, and sensitivity to macroeconomic factors. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
